{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:30:05Z","timestamp":1793608205988,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270190"],"award-info":[{"award-number":["82270190"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.03.017","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:59:45Z","timestamp":1774630785000},"page":"e811-e819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Seven-day Venetoclax Combined With Dose-adjusted Intensive Chemotherapy as Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Ting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanchen","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanliang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunya","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxian","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-0301","authenticated-orcid":false,"given":"Kaiqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.clml.2026.03.017_bib0001","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.03.017_bib0002","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","article-title":"Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study","volume":"117","author":"Ohtake","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2026.03.017_bib0003","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.03.017_bib0004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial","volume":"32","author":"Willemze","year":"2014","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2026.03.017_bib0005","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","article-title":"Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study","volume":"30","author":"Holowiecki","year":"2012","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.03.017_bib0006","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","article-title":"Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial","volume":"14","author":"Jin","year":"2013","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.clml.2026.03.017_bib0007","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1002\/cncr.30883","article-title":"A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.03.017_bib0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-023-00409-y","article-title":"Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial","volume":"12","author":"Suo","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.03.017_bib0009","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2026.03.017_bib0010","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2026.03.017_bib0011","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.clml.2026.03.017_bib0012","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.03.017_bib0013","first-page":"387","article-title":"Venetoclax combined with dose-reduced HAD as induction treatment for patients with de-novo acute myeloid leukemia]","volume":"45","author":"Yan","year":"2024","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"issue":"12","key":"10.1016\/j.clml.2026.03.017_bib0014","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2026.03.017_bib0015","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.017_bib0016","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.1002\/ajh.23884","article-title":"Comparison of 60 or 90 mg\/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics","volume":"90","author":"Devillier","year":"2015","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.clml.2026.03.017_bib0017","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2017.72.8618","article-title":"Prospective randomized comparison of Idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.03.017_bib0018","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2026.03.017_bib0019","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","article-title":"Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia","volume":"33","author":"Chen","year":"2015","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.017_bib0020","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1186\/s12885-020-07222-4","article-title":"Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"issue":"30","key":"10.1016\/j.clml.2026.03.017_bib0021","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.03.017_bib0022","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.clml.2026.03.017_bib0023","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:14:41Z","timestamp":1793607281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026000947"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seven-day Venetoclax Combined With Dose-adjusted Intensive Chemotherapy as Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}